South Korea
· Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 583.00 billion. The enterprise value is 649.39 billion.
| Market Cap | 583.00B |
| Enterprise Value | 649.39B |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
L&C BIO Co.,LTD has 22.68 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 22.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 29.90% |
| Owned by Institutions (%) | 14.95% |
| Float | 15.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.32 |
| PB Ratio | 4.06 |
| P/TBV Ratio | 4.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 70.43, with an EV/FCF ratio of -15.46.
| EV / Earnings | -108.94 |
| EV / Sales | 9.27 |
| EV / EBITDA | 70.43 |
| EV / EBIT | 267.78 |
| EV / FCF | -15.46 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.11 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 8.98 |
| Debt / FCF | -1.97 |
| Interest Coverage | 0.39 |
Financial Efficiency
Return on equity (ROE) is -3.64% and return on invested capital (ROIC) is 0.64%.
| Return on Equity (ROE) | -3.64% |
| Return on Assets (ROA) | 0.58% |
| Return on Capital (ROIC) | 0.64% |
| Revenue Per Employee | 538.70M |
| Profits Per Employee | -45.85M |
| Employee Count | 130 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.37 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 20,700.40 |
| 200-Day Moving Average | 20,268.65 |
| Relative Strength Index (RSI) | 63.64 |
| Average Volume (20 Days) | 221,573 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 70.03 billion and -5.96 billion in losses. Loss per share was -262.78.
| Revenue | 70.03B |
| Gross Profit | 33.97B |
| Operating Income | 2.43B |
| Pretax Income | -5.78B |
| Net Income | -5.96B |
| EBITDA | 9.22B |
| EBIT | 2.43B |
| Loss Per Share | -262.78 |
Balance Sheet
The company has 26.69 billion in cash and 82.84 billion in debt, giving a net cash position of -56.15 billion or -2,475.04 per share.
| Cash & Cash Equivalents | 26.69B |
| Total Debt | 82.84B |
| Net Cash | -56.15B |
| Net Cash Per Share | -2,475.04 |
| Equity (Book Value) | 153.73B |
| Book Value Per Share | 6,325.44 |
| Working Capital | 10.16B |
Cash Flow
In the last 12 months, operating cash flow was -15.72 billion and capital expenditures -26.28 billion, giving a free cash flow of -41.99 billion.
| Operating Cash Flow | -15.72B |
| Capital Expenditures | -26.28B |
| Free Cash Flow | -41.99B |
| FCF Per Share | -1,851.15 |
Margins
Gross margin is 48.50%, with operating and profit margins of 3.46% and -8.51%.
| Gross Margin | 48.50% |
| Operating Margin | 3.46% |
| Pretax Margin | -8.26% |
| Profit Margin | -8.51% |
| EBITDA Margin | 13.17% |
| EBIT Margin | 3.46% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.20%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.20% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.20% |
| Earnings Yield | -1.02% |
| FCF Yield | -7.20% |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 4.16.
| Altman Z-Score | 4.16 |
| Piotroski F-Score | n/a |